EMERGING GENE EDITING APPROACHES FOR CFTR CORRECTION IN CYSTIC FIBROSIS
Scientific Records · 18.07.2026 · 66
DOI: 10.62324/journal.sr/2026.068 ↗Kurz gefasst
Fachartikel in der Zeitschrift Scientific Records, online erschienen am 18.07.2026.
Abstract (Originalsprache)
Cystic fibrosis (CF) is a life threatening autosomal recessive disorder caused by pathogenic variants in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which encodes a chloride and bicarbonate ion channel essential for epithelial fluid homeostasis.Dysfunctional CFTR impairs ion transport across epithelial surfaces, leading to dehydrated mucus, chronic respiratory infections, progressive lung damage, pancreatic insufficiency, and multisystem complications.Although CFTR modulators and symptomatic therapies have significantly improved patient outcomes and survival, they remain mutation specific and do not provide a definitive cure, particularly for patients with rare or severe mutations.Recent advances in genome engineering have introduced promising strategies for directly correcting CFTR mutations at the DNA and RNA levels.Technologies such as CRISPR-Cas systems, base editing, prime editing, and RNA targeting approaches offer the potential to repair disease causing mutations rather than merely alleviating symptoms.Preclinical studies in patient derived organoids, airway epithelial cells, stem cell models, and animal systems have demonstrated encouraging results in restoring CFTR function.In parallel, the development of viral and non-viral delivery systems has improved the targeted delivery of gene editing components to respiratory tissues.Despite these advancements, several challenges remain, including off-target effects, immune responses, delivery barriers in the airway environment, long term genomic stability, and ethical considerations related to genome modification.Ongoing progress in precision medicine, artificial intelligence assisted editing design, and personalized therapeutic strategies is expected to enhance safety and efficiency.This review summarizes the pathophysiology of CFTR dysfunction and critically evaluates emerging gene editing technologies for cystic fibrosis, highlighting their therapeutic potential, current limitations, and future clinical prospects toward a durable and potentially curative treatment.
Zitieren
APA
(2026). EMERGING GENE EDITING APPROACHES FOR CFTR CORRECTION IN CYSTIC FIBROSIS. Scientific Records, 66. https://doi.org/10.62324/journal.sr/2026.068
Vancouver
EMERGING GENE EDITING APPROACHES FOR CFTR CORRECTION IN CYSTIC FIBROSIS. Scientific Records. 2026:66. doi:10.62324/journal.sr/2026.068
BibTeX
@article{euvimed2026,
title = {EMERGING GENE EDITING APPROACHES FOR CFTR CORRECTION IN CYSTIC FIBROSIS},
journal = {Scientific Records},
year = {2026},
pages = {66},
doi = {10.62324/journal.sr/2026.068}
}
EUVIMED